Kura Oncology (NASDAQ:KURA) was downgraded by equities researchers at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday.

Several other research analysts also recently issued reports on the company. BidaskClub downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research note on Thursday, July 19th. HC Wainwright set a $31.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research report on Tuesday, August 7th. Oppenheimer increased their target price on shares of Kura Oncology from $27.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, July 9th. Finally, Zacks Investment Research raised shares of Kura Oncology from a “sell” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.33.

Shares of Kura Oncology stock traded down $1.17 on Friday, hitting $14.38. The stock had a trading volume of 251,300 shares, compared to its average volume of 283,534. Kura Oncology has a twelve month low of $12.10 and a twelve month high of $24.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.22 and a quick ratio of 10.22. The company has a market capitalization of $603.81 million, a P/E ratio of -9.46 and a beta of 4.19.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.45). Equities analysts anticipate that Kura Oncology will post -1.73 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Kura Oncology by 25.5% during the 2nd quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock valued at $36,440,000 after purchasing an additional 406,963 shares during the period. Victory Capital Management Inc. acquired a new stake in Kura Oncology during the 2nd quarter valued at approximately $27,104,000. Eagle Asset Management Inc. acquired a new stake in Kura Oncology during the 2nd quarter valued at approximately $24,881,000. Carillon Tower Advisers Inc. acquired a new stake in Kura Oncology during the 2nd quarter valued at approximately $16,853,000. Finally, Sio Capital Management LLC increased its position in Kura Oncology by 27.4% during the 2nd quarter. Sio Capital Management LLC now owns 837,604 shares of the company’s stock valued at $15,244,000 after purchasing an additional 180,193 shares during the period. 77.28% of the stock is owned by institutional investors and hedge funds.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Recommended Story: What are trading strategies for the 52-week high/low?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.